Audio recordings of interviews with 42 psychiatric patients (10 schizophrenic, 11 manic, 11 schizoaffective, and 10 depressive patients) and 10 hospitalized orthopedic patients were rated for the presence of verbal communication impairment using the system developed by Andreasen. The definitions of some categories required additional qualifying statements before agreement could be reached on their meaning and applicability in specific circumstances. Nevertheless, the results indicate that the scales can be used reliably by carefully trained, nonprofessional raters. Significant differences were found between diagnostic groups with regard to the frequency and severity of some categories of communication impairment, but the general pattern of results supports previous suggestions that these problems are not pathognomonic of schizophrenia. Based on our experience, we suggest a few changes that might be helpful to other investigators, both in the procedures used for obtaining samples of speech and the definitions of subcategories of verbal communication impairment.
A group of 17 white male chronic schizophrenic subjects were divided on the basis of plexus visualization score (PVS). High and low PVS subjects were compared to each other and to low PVS controls on measures of platelet monamine oxidase (MAO), rbc catechol-o-methyl transferase (COMT), and plasma dopamine-beta-hydroxylase (D beta H). There were no differences between high and low PVS subjects on any biochemical variable. Schizophrenic subjects had lower platelet MAO activity than controls. Platelet MAO and rbc COMT were significantly correlated in schizophrenic subjects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.